MedX Health Names Sylvain Desjeans as Chief Revenue Officer

MedX Health Corp. (MedX) has appointed Sylvain Desjeans as chief revenue officer. With more than 30 years of healthcare industry experience, Desjeans is a seasoned leader who has successfully implemented and led large-scale strategic growth plans and global product licensing initiatives for international pharmaceutical and medical companies. He comes to MedX from tenures as country manager (Canada) for Aspen Pharmacare and senior leadership positions at Accucaps Industries Limited and Biovail Pharmaceuticals.
 
Desjeans will lead market access, customer acquisition, engagement and marketing for MedX’s teledermatology offering as the company accelerates its international expansion efforts and continues the growth of its network of approved clinical partners across Canada, including Empower Clinics. Desjeans will also work closely with the chair of MedX’s Medical Advisory Board, Dr. Trevor Champagne, on the company’s artificial intelligence technology, driving ongoing innovation and patient-driven product development.
 
“Sylvain brings a wealth of experience to our growing team as we continue to scale our operations to meet international demand and increasing uptake within the North American market,” said Robert von der Porten, acting CEO and board chairman. “His experience, leadership and relationships will secure further market access as we set our sights on new opportunities given the growing need for teledermatology to support healthcare systems, globally. His background in dermatology—and specifically working with dermatologists—will bring value to our partner clinicians and customers.”

MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
 
Desjeans stated, “MedX is poised for significant international market expansion with its best-in-class SIAscopy skin-scanning device and DermSecure platform. This technology reduces the strain on healthcare systems by offering a truly patient-centric experience, which ultimately improves patient outcomes.”
 
Teledermatology, a subspecialty of dermatology that offers safe and effective virtual care—patient assessment and diagnosis—at a distance, eliminates the need for in-person appointments. With the world navigating through ongoing COVID-19 recovery measures, teledermatology’s advancement has never been more critical to patient care and outcomes.
 
MedX, headquartered in Mississauga, Ontario, is a medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in SIAMETRICS, a well-regarded research system used to assess treatment effectiveness of a variety of skin conditions, including burns. The company’s SIAscope and other devices are manufactured in its ISO 13485 certified facility. The SIAscope is a handheld device that uses patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with the company’s software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, U.S. Food and Drug Administration, TGA and CE cleared for use in Canada, the United States, Australia, New Zealand, the European Union, Turkey, and Brazil. MedX also designs, manufactures, and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.